We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · August 30, 2021

Small Study Finds Bempegaldesleukin Plus Nivolumab Safe and Effective in First-Line Metastatic Melanoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
J. Clin. Oncol 2021 Jul 13;[EPub Ahead of Print], A Diab, SS Tykodi, GA Daniels, M Maio, BD Curti, KD Lewis, S Jang, E Kalinka, I Puzanov, AI Spira, DC Cho, S Guan, E Puente, T Nguyen, U Hoch, SL Currie, W Lin, MA Tagliaferri, J Zalevsky, M Sznol, ME Hurwitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading